HGH (Somatropin) vs PEG-MGF (Pegylated Mechano Growth Factor)

Side-by-side comparison of mechanisms, dosing, interactions, and stacking potential.

✅ Stacking Partners — These compounds are commonly used together and may have synergistic effects.
⚠️ Known Interaction
LOW Complementary — HGH drives IGF-1 systemically, PEG-MGF provides targeted satellite cell activation.
HGH (Somatropin)PEG-MGF (Pegylated Mechano Growth Factor)
CategoryGrowth FactorsGrowth Factors
Standard DoseResearch indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).Research indicates 200-500 mcg administered 2-3 times per week via subcutaneous or intramuscular injection.
TimingBedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.On non-training days or several hours post-workout (to avoid competing with natural MGF pulse). Unlike native MGF, timing is more flexible due to extended half-life.
Cycle DurationContinuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.4-8 week cycles.
Evidence Levelstrong_humananimal_plus_anecdotal
A

HGH (Somatropin)

Growth Factors

Mechanism

Human Growth Hormone (somatropin) is a 191-amino acid single-chain polypeptide produced by anterior pituitary somatotrophs. It binds the GH receptor (GHR), activating JAK2-STAT5 signaling and MAP kinase pathways. Systemically, HGH upregulates hepatic IGF-1 production, which mediates most of its anabolic effects through IGF-1R/PI3K/Akt/mTOR-driven protein synthesis. Direct GH effects include lipolysis activation, insulin antagonism, chondrocyte/osteoblast stimulation, and enhanced collagen synthesis. Effects are divided into direct (lipolysis, insulin antagonism) and indirect (IGF-1-mediated growth and anabolism).

Standard Dosing

Research indicates 1-2 IU daily for anti-aging and general optimization. 2-4 IU daily for body composition. 4-8+ IU daily in clinical GH deficiency (physician-supervised only).

Timing

Bedtime injection (mimics natural nocturnal GH surge) or morning fasted. Split dosing (AM + pre-bed) for higher doses. Always on empty stomach — carbohydrates blunt GH action.

Cycle Duration

Continuous use is common in anti-aging protocols. 6-12 month minimum for full benefits. Clinical GHD treatment is typically lifelong.

Side Effects

  • Water retention/edema
  • Joint pain (arthralgia)
  • Carpal tunnel syndrome
  • Insulin resistance/elevated blood glucose
  • Gynecomastia
  • Numbness/tingling
  • Headache
  • Potential organ growth at high doses
  • Jaw/hand growth with chronic supraphysiological use

Contraindications

  • Active cancer or active tumors
  • Diabetic retinopathy (proliferative)
  • Acute critical illness
  • Closed epiphyses with active acromegaly features
  • Prader-Willi syndrome with severe obesity/respiratory impairment
  • Pregnancy and breastfeeding

Best Stacking Partners

CJC-1295/Ipamorelin (use one or the other — not GHS + exogenous GH)BPC-157TB-500

Mechanism

PEG-MGF is the pegylated form of Mechano Growth Factor, where polyethylene glycol (PEG) molecules are covalently attached to protect against rapid enzymatic breakdown. This extends the half-life from 5-7 minutes (native MGF) to approximately 48-72 hours. Like native MGF, it activates satellite cell proliferation, promotes muscle fiber regeneration and hypertrophy, and supports tissue repair. The extended half-life allows for systemic distribution rather than purely local action, enabling subcutaneous rather than intramuscular administration.

Standard Dosing

Research indicates 200-500 mcg administered 2-3 times per week via subcutaneous or intramuscular injection.

Timing

On non-training days or several hours post-workout (to avoid competing with natural MGF pulse). Unlike native MGF, timing is more flexible due to extended half-life.

Cycle Duration

4-8 week cycles.

Side Effects

  • Injection site soreness
  • Mild hypoglycemia
  • Water retention
  • Localized swelling

Contraindications

  • Active cancer
  • Pregnancy and breastfeeding
  • Under 25 years of age

Best Stacking Partners

HGHIGF-1 LR3BPC-157

Not sure which is right for you?

Take our free assessment to get personalized recommendations based on your health goals, current stack, and biomarkers.

Get Your Free Protocol →or take the assessment →